[go: up one dir, main page]

MX2007004479A - Compuestoss para supresion sin sentido y metodos para su uso. - Google Patents

Compuestoss para supresion sin sentido y metodos para su uso.

Info

Publication number
MX2007004479A
MX2007004479A MX2007004479A MX2007004479A MX2007004479A MX 2007004479 A MX2007004479 A MX 2007004479A MX 2007004479 A MX2007004479 A MX 2007004479A MX 2007004479 A MX2007004479 A MX 2007004479A MX 2007004479 A MX2007004479 A MX 2007004479A
Authority
MX
Mexico
Prior art keywords
compounds
methods
compositions
present
nonsense suppression
Prior art date
Application number
MX2007004479A
Other languages
English (en)
Inventor
Guangming Chen
Neil Almstead
Gary M Karp
Ellen Welch
Richard Wilde
Jeffrey A Campbell
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2007004479A publication Critical patent/MX2007004479A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/24—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to three ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C07F9/65306—Five-membered rings containing two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invencion se relaciona con metodos, compuestos y composiciones para tratar o prevenir enfermedades asociadas con mutaciones sin sentido en un ARNm al administrar los compuestos o composiciones de la presente invencion; mas en particular, la presente invencion se relaciona con metodos, compuestos y composiciones para suprimir la terminacion de traduccion prematura asociada con una mutacion sin sentido en un ARNm.
MX2007004479A 2004-10-13 2005-10-13 Compuestoss para supresion sin sentido y metodos para su uso. MX2007004479A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US61767004P 2004-10-13 2004-10-13
US61765304P 2004-10-13 2004-10-13
US61765504P 2004-10-13 2004-10-13
US61763304P 2004-10-13 2004-10-13
US61763404P 2004-10-13 2004-10-13
US62417004P 2004-11-03 2004-11-03
PCT/US2005/036673 WO2006044456A1 (en) 2004-10-13 2005-10-13 Compounds for nonsense suppression, and methods for their use

Publications (1)

Publication Number Publication Date
MX2007004479A true MX2007004479A (es) 2007-06-18

Family

ID=35517967

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2007004479A MX2007004479A (es) 2004-10-13 2005-10-13 Compuestoss para supresion sin sentido y metodos para su uso.
MX2007004484A MX2007004484A (es) 2004-10-13 2005-10-13 Compuestos de pirazol o triazol y su uso para la fabricacion de un medicamento para tratar las enfermedades relacionadas con la mutacion somatica.
MX2007004487A MX2007004487A (es) 2004-10-13 2005-10-13 Compuestos para supresion sin sentido, y metodos para su uso.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2007004484A MX2007004484A (es) 2004-10-13 2005-10-13 Compuestos de pirazol o triazol y su uso para la fabricacion de un medicamento para tratar las enfermedades relacionadas con la mutacion somatica.
MX2007004487A MX2007004487A (es) 2004-10-13 2005-10-13 Compuestos para supresion sin sentido, y metodos para su uso.

Country Status (11)

Country Link
US (10) US20080269191A1 (es)
EP (13) EP1815206B1 (es)
JP (3) JP2008515992A (es)
KR (3) KR20070067201A (es)
AU (3) AU2005295730A1 (es)
BR (2) BRPI0515995A (es)
CA (5) CA2582885A1 (es)
IL (3) IL182459A0 (es)
MX (3) MX2007004479A (es)
SG (2) SG156640A1 (es)
WO (5) WO2006044502A2 (es)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010106A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
EP3178816A1 (en) 2003-04-11 2017-06-14 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
AU2005295730A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
EP1940801A2 (en) * 2005-10-14 2008-07-09 NeuroSearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
WO2007047706A2 (en) * 2005-10-17 2007-04-26 Children's Hospital Methods and compositions for regulating gene expression
NZ570625A (en) * 2006-02-10 2011-10-28 Biomarin Iga Ltd Treatment of duchenne muscular dystrophy
CN101505739A (zh) 2006-03-30 2009-08-12 Ptc医疗公司 由具有无义突变的dna生产功能蛋白的方法以及相关疾病的治疗
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PT2674428T (pt) 2006-04-07 2016-07-14 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
AU2007300542B2 (en) * 2006-09-25 2012-05-17 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
KR100858357B1 (ko) * 2006-10-02 2008-09-11 (주) 디지탈바이오텍 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008157407A2 (en) * 2007-06-13 2008-12-24 University Of Virginia Patent Foundation Thiadiazole, oxadiazole and triazole derivatives for treating leukemia
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
ES2556080T3 (es) 2007-11-16 2016-01-12 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
UA102534C2 (xx) 2007-12-07 2013-07-25 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ)
NZ616097A (en) 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
JP5369854B2 (ja) 2008-04-21 2013-12-18 住友化学株式会社 有害節足動物防除組成物および縮合複素環化合物
EP2300481B1 (en) 2008-05-30 2015-09-30 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
BRPI0914629A2 (pt) * 2008-06-24 2019-09-24 Irm Llc compostos e métodos para a modulação de receptores acoplados à proteína g
US9006454B2 (en) * 2009-04-02 2015-04-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
WO2011022393A2 (en) * 2009-08-17 2011-02-24 The Brigham And Women's Hospital, Inc. Phosphatidylcholine transfer protein inhibitors
ES2533798T3 (es) 2009-10-12 2015-04-14 Bayer Cropscience Ag 1-(pirid-3-il)-pirazol y 1-(pirimid-5-il)- pirazol como agentes para combatir parásitos
US20130040983A1 (en) * 2010-01-08 2013-02-14 Jean-Michel Vernier Raf kinase inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2711481C2 (ru) 2010-03-25 2020-01-17 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА
NZ602795A (en) 2010-04-07 2015-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN102917692A (zh) 2010-04-07 2013-02-06 弗特克斯药品有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012027247A2 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103732213A (zh) 2011-06-07 2014-04-16 帕里昂科学公司 治疗方法
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
AU2012335714B2 (en) 2011-11-08 2017-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US20130186801A1 (en) 2012-01-25 2013-07-25 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
KR101452235B1 (ko) * 2012-02-03 2014-10-22 서울대학교산학협력단 신규한 피리미딘계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 ｒａｇｅ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
EP3366680B1 (en) 2012-05-29 2020-05-13 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
PL2914248T5 (pl) 2012-11-02 2024-01-15 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
MX2015007205A (es) 2012-12-06 2016-03-31 Quanticel Pharmaceuticals Inc Inhibidores de la desmetilasa de histona.
CN104995178B (zh) 2012-12-17 2018-06-26 帕里昂科学公司 3，5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
JP6360878B2 (ja) 2013-03-12 2018-07-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
WO2014163934A1 (en) * 2013-03-13 2014-10-09 Dow Agrosciences Llc Preparation of 1,3-(substituted-diaryl)-1,2,4-triazoles
HK1218537A1 (zh) 2013-03-15 2017-02-24 Discoverybiomed Inc. 香豆素衍生物以及用於治疗过度增生性疾病的方法
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152132A1 (en) * 2013-03-15 2014-09-25 Monsanto Technology Llc N-,c-disubstituted azoles for controlling nematode pests
CN105121437B (zh) * 2013-03-15 2018-12-04 发现生物医药公司 香豆素衍生物和用于治疗囊性纤维化、慢性阻塞性肺病和错误折叠蛋白质病症的方法
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
FR3011468B1 (fr) * 2013-10-04 2015-12-04 Inventiva Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
WO2015054283A1 (en) * 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
SI3057953T1 (sl) 2013-10-17 2018-12-31 Vertex Pharmaceuticals Incorporated Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk
TWI636978B (zh) 2014-03-06 2018-10-01 美商Ｐｔｃ治療公司 １，２，４－二唑苯甲酸之鹽及醫藥組合物
CA2944140C (en) 2014-04-15 2022-10-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
AU2015328174B2 (en) 2014-10-06 2020-05-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
WO2016097004A1 (en) * 2014-12-17 2016-06-23 King's College London BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS
JP6797800B2 (ja) * 2014-12-19 2020-12-09 ガルデルマ・リサーチ・アンド・デヴェロップメント 新規化合物、その合成方法、並びに医薬品及び化粧品におけるその使用
US10328064B2 (en) 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
BR112018001414B1 (pt) * 2015-07-24 2022-02-22 Syngenta Participations Ag Compostos derivados de 1, 2, 4-triazol do ponto de vista pesticida com substituintes contendo enxofre, composição pesticida, método para controle de pragas e método para aproteção de material de propagação de plantas do ataque por pragas
KR20180081516A (ko) 2015-10-30 2018-07-16 피티씨 테라퓨틱스, 인크. 간질 치료 방법
WO2017108569A1 (en) 2015-12-22 2017-06-29 Syngenta Participations Ag Pesticidally active pyrazole derivatives
CA3048193A1 (en) * 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
CN109476635B (zh) 2016-04-29 2021-07-13 Fgh生物科技公司 用于治疗疾病的二取代吡唑类化合物
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
PL3730487T3 (pl) 2016-06-13 2022-08-16 Gilead Sciences, Inc. Pochodne azetydyny jako modulatory fxr (nr1h4)
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
WO2018049080A1 (en) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
AU2017335648B2 (en) 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
EP3558970B1 (en) * 2016-12-20 2021-09-01 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
US11439623B2 (en) * 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
WO2019040724A1 (en) * 2017-08-23 2019-02-28 The Regents Of The University Of Michigan SMALL MYC INHIBITOR MOLECULES AND USES THEREOF
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
US11203578B2 (en) 2017-11-23 2021-12-21 Universita'degli Studi Dipalermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
US20210163425A1 (en) * 2017-12-20 2021-06-03 Gyeonggido Business & Science Accelerator Triazole derivative and use thereof
WO2019185736A1 (de) * 2018-03-29 2019-10-03 Explo Engineering Ag Vorrichtung und verfahren zur erzeugung von druckwellen hoher amplitude
WO2019209777A1 (en) * 2018-04-23 2019-10-31 The Curators Of The University Of Missouri Improved crispr therapy
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
PE20212177A1 (es) * 2019-03-26 2021-11-09 Neuropore Therapies Inc Compuestos y composiciones como moduladores de la senalizacion de tlr
KR102663365B1 (ko) * 2019-09-25 2024-05-08 한국원자력의학원 신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
CN114728909A (zh) * 2019-09-25 2022-07-08 韩国原子力医学院 含有新型三氟甲基苯基吡唑衍生物作为活性成分用于预防或治疗癌症的组合物
CN114727977A (zh) 2019-11-19 2022-07-08 特维娜有限公司 化合物和化合物s1p1调节剂的制备方法
CA3162280A1 (en) * 2019-12-10 2021-06-17 The Trustees Of Indiana University 4,5-dihydro-1h-pyrazolyl compounds as repication protein a (rpa)-dna interaction inhibitors
KR102847693B1 (ko) * 2019-12-27 2025-08-18 서울대학교산학협력단 옥사디아졸 유도체를 포함하는 비만의 예방 또는 치료용 조성물
EP3912628A1 (en) 2020-05-20 2021-11-24 Institut de Recherche en Semiochimie et Ethologie Appliquée Nucleoside analogues to inhibit the main protease of a coronavirus
US20240139214A1 (en) * 2021-02-04 2024-05-02 Kyushu University, National University Corporation Agent for suppressing il-31 production and pharmaceutical composition containing the same
CN119350257B (zh) * 2021-06-28 2025-11-18 广西医科大学 三氮唑化合物
EP4173485A1 (en) * 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein aggregation inhibiting compounds for plant disease control
JP2025510413A (ja) * 2022-03-25 2025-04-14 バスセラ カンパニー，リミテッド ３－フェニルイソオキサゾール誘導体、及びそれを有効成分として含む眼疾患の予防用又は治療用医薬組成物
CN120303267A (zh) 2022-11-03 2025-07-11 森托尼克思有限公司 针对tau聚集体的选择性配体
GB202300021D0 (en) * 2023-01-03 2023-02-15 Thirtyfivebio Ltd Compounds
WO2025116596A1 (ko) * 2023-11-29 2025-06-05 가천대학교 산학협력단 신규 화합물 및 이를 포함하는 안질환 예방 또는 치료용 조성물
CN119144004B (zh) * 2024-08-12 2025-10-28 兰州大学 一种m-hof材料及其制备方法和在氢氧根离子识别中的应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153017A (en) * 1961-06-29 1964-10-13 Eastman Kodak Co Nitrogen-containing linear polyesters from amino methyl cyclohexanol and dicarboxylic acids
CH522432A (de) 1967-02-07 1972-06-30 Ciba Geigy Ag Verwendung von v-Triazolen als Schutzmittel für nichttextile organische Substrate gegen UV-Strahlen
GB1263940A (en) * 1968-08-02 1972-02-16 Innothera Lab Sa 0-phenyl-pyrroles
GB1248070A (en) 1968-12-16 1971-09-29 Science Union & Cie Thiazolyl-benzoic acid derivatives and process for preparing them
US3803162A (en) 1969-10-03 1974-04-09 Sandoz Ltd 7-triazolyl-3-phenylcoumarins
US3679669A (en) * 1970-09-23 1972-07-25 Ciba Geigy Ag Phenyl-1,3,4-oxdiazole compounds
US3882138A (en) * 1971-08-09 1975-05-06 Uniroyal Inc Oxazole and oxadiazole benzoic acid derivatives as herbicides
US3964896A (en) 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3948937A (en) 1972-02-29 1976-04-06 E. I. Du Pont De Nemours And Company Pyrazole plant growth regulants
US4035175A (en) * 1974-07-29 1977-07-12 Uniroyal Inc. Method of retarding the growth of plants using certain oxadiazolyl, oxazolyl or thiadiazolyl benzoic acid derivatives
US3947263A (en) * 1974-07-29 1976-03-30 Uniroyal, Inc. Plant growth regulants
AU497898B2 (en) 1975-01-10 1979-01-18 Commonwealth Scientific And Industrial Research Organisation Plant growth regulating method and composition for use therein
US4038285A (en) * 1975-06-25 1977-07-26 E. I. Du Pont De Nemours And Company 1-(2-carboxyaryl)-4-arylimidazoles and 1-(2-carboxyaryl)-3-aryl-1,2,4-triazoles
US4032644A (en) * 1975-12-29 1977-06-28 Sandoz, Inc. Isoxazolyl benzoic acids
DE2722331A1 (de) * 1976-05-18 1977-11-24 Ricoh Kk 1,3,4-oxadiazolderivate sowie diese enthaltende elektrophotographische aufzeichnungsmaterialien
US4166732A (en) * 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4140515A (en) * 1977-05-12 1979-02-20 Monsanto Company Aryl-3-isoxazole benzoates as plant growth regulants and herbicides
US4268299A (en) * 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) * 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
CA1125768A (en) * 1978-10-31 1982-06-15 Hoffmann-La Roche Limited Benzoxazole derivatives
US4229204A (en) * 1978-12-04 1980-10-21 Monsanto Company Trifluoromethylphenyl isoxazolyl benzoates
JPS58177977A (ja) 1982-04-09 1983-10-18 Grelan Pharmaceut Co Ltd ４−フエニルピラゾ−ル類
SU1063100A1 (ru) * 1982-04-22 1985-06-30 Предприятие П/Я А-7850 Жидкокристаллический материал дл электрооптических устройств
US4760066A (en) * 1982-09-21 1988-07-26 Wayne State University Method for treating human tumor cell metastasis
US4546113A (en) * 1983-04-14 1985-10-08 Pfizer Inc. Antiprotozoal diamidines
DD226883A1 (de) * 1984-07-30 1985-09-04 Neubauer T Paedagog Hochschule Verfahren zur herstellung von 1,3-disubstituierten 5-alkoxy-1,2,4-triazolen und 1,2,4-triazolin-5-onen
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
US5260451A (en) * 1989-05-11 1993-11-09 Merckle Gmbh Substituted pyrrole compounds and use thereof in pharmaceutical compositions
US5022915A (en) * 1990-03-01 1991-06-11 Ici Americas Inc. Substituted 2,4-diarylpyrimidines and their use as herbicides
ES2092580T3 (es) 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
FR2672050A1 (fr) * 1991-01-30 1992-07-31 Atochem Diaryl-2,5 oxadiazoles-1,3,4 hydroxyester, hydroxyacide et acetoxyacide, leur procede de synthese.
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
IL112290A (en) * 1994-01-12 1999-01-26 Novartis Ag Transformed aryl and the troiryl pyrimidines and herbicides containing them
US5521189A (en) * 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
PT788511E (pt) * 1994-10-07 2003-04-30 Fujisawa Pharmaceutical Co Hexapeptidos ciclicos com actividade antibiotica
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
DE19536811A1 (de) * 1995-10-02 1997-04-03 Basf Ag Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel
JP3995716B2 (ja) * 1996-03-18 2007-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合環含有カルボン酸誘導体
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
AU4945697A (en) 1996-10-09 1998-05-05 Novartis Ag Solid phase synthesis of heterocyclic compounds
HUP0002966A3 (en) * 1996-11-25 2001-10-29 Procter & Gamble 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
WO1998028421A1 (en) 1996-12-20 1998-07-02 Human Genome Sciences, Inc. Human oncogene induced secreted protein i
DE69818083T2 (de) 1997-10-06 2004-07-08 Abbott Gmbh & Co. Kg INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE
SI1023063T1 (en) * 1997-10-06 2004-02-29 Abbott Gmbh & Co. Kg INDENO(1,2-c), NAPHTHO(1,2-c)- AND BENZO(6,7)CYCLOHEPTA(1,2-c)PYRAZOLE DERIVATIVES
DE19816880A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
EP1053247A1 (en) * 1998-02-09 2000-11-22 Fujisawa Pharmaceutical Co., Ltd. Antifungal cyclohexapeptides
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
DE19904406A1 (de) 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolcarbonsäuren
DE19904389A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
SK8452002A3 (en) 1999-12-16 2002-11-06 Schering Corp Substituted 4-(phenyl or pyridyl)imidazole derivatives, pharmaceutical composition comprising the same and use thereof
US7729756B2 (en) 2000-01-18 2010-06-01 Siemens Aktiengesellschaft Measurement system for examining a section of tissue on a patient and the use of a measurement system of this type
US6800604B2 (en) 2000-02-11 2004-10-05 Genentech, Inc. Polypeptides that inhibit human serum-induced cleavage of hepatocyte growth factor
US6605615B2 (en) * 2000-03-01 2003-08-12 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
GB0012362D0 (en) 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
HU227630B1 (hu) * 2000-05-22 2011-10-28 Aventis Pharma Inc Arilmetilamin-származékok triptáz gátlóként való alkalmazásra és ezeket tartalmazó gyógyszerkészítmények
AU2002216649A1 (en) * 2000-10-31 2002-05-15 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
CA2438991C (en) * 2001-02-21 2010-08-17 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CN1522251A (zh) 2001-05-09 2004-08-18 ס������ũҩ��ʽ���� 唑化合物及其制备方法和应用
JP2003026663A (ja) 2001-05-09 2003-01-29 Takeda Chem Ind Ltd アゾール化合物、その製造法および用途
US7223791B2 (en) * 2001-06-26 2007-05-29 Takeda Pharmaceutical Company Limited Function regulator for retinoid relative receptor
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
DE10136066A1 (de) * 2001-07-25 2003-02-13 Bayer Cropscience Ag Tetrahydropyridazin-Derivate
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
WO2003027101A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
CA2469821C (en) * 2001-12-18 2009-10-20 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
DE60223720T2 (de) 2001-12-18 2008-10-30 Merck & Co., Inc. Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
US7371767B2 (en) * 2001-12-21 2008-05-13 Merck & Co., Inc. Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
AU2003222648A1 (en) 2002-05-13 2003-12-02 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
NZ548796A (en) 2002-05-15 2008-01-31 Janssen Pharmaceutica Nv N-substituted trycyclic 3-aminopyrazoles as PDFG receptor inhibitors
CA2493816A1 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2004009533A1 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
CA2493458A1 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
US20060235021A1 (en) 2002-08-13 2006-10-19 Wesley Blackaby Phenylpyridazine derivatives as ligands for gaba receptors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
PL379544A1 (pl) * 2002-09-09 2006-10-02 Amgen Inc. 1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych
WO2004046122A2 (en) * 2002-11-16 2004-06-03 Oxford Glycosciences (Uk) Ltd Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
US20040176264A1 (en) * 2002-12-30 2004-09-09 The Procter & Gamble Company Rinse aid composition containing water-soluble metal salt for use in automatic dishwashing for glassware corrosion protection
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7514446B2 (en) 2003-02-20 2009-04-07 Smithkline Beecham Corporation Pyrimidine compounds
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
EP3178816A1 (en) 2003-04-11 2017-06-14 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
RU2379292C2 (ru) 2003-04-18 2010-01-20 Мемори Фармасьютиклз Корпорейшн Производные пиразола в качестве ингибиторов фосфодиэстеразы 4
JP4942654B2 (ja) 2004-08-23 2012-05-30 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体薬剤、製剤及び治療的使用
AU2005295730A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2007059356A2 (en) * 2005-11-19 2007-05-24 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
EP2284154A1 (en) * 2009-07-29 2011-02-16 Argon Pharma S.L. Antitumor 1,2-diphenylpyrrole compounds and their preparation process

Also Published As

Publication number Publication date
WO2006044503A2 (en) 2006-04-27
CA2583976A1 (en) 2006-04-27
AU2005295778A1 (en) 2006-04-27
US9051342B2 (en) 2015-06-09
US9611230B2 (en) 2017-04-04
IL182459A0 (en) 2007-07-24
US20080280869A1 (en) 2008-11-13
WO2006044505A3 (en) 2006-07-06
US20160229818A1 (en) 2016-08-11
EP2301536B1 (en) 2014-04-09
EP2402323A3 (en) 2012-05-30
US20080119473A1 (en) 2008-05-22
EP2311455B1 (en) 2015-07-15
JP2008515992A (ja) 2008-05-15
EP2301538A1 (en) 2011-03-30
MX2007004487A (es) 2007-06-18
JP2008515985A (ja) 2008-05-15
US20150274674A1 (en) 2015-10-01
US20090253699A1 (en) 2009-10-08
EP1799207A2 (en) 2007-06-27
CA2583971A1 (en) 2006-04-27
BRPI0515995A (pt) 2008-08-19
US7902235B2 (en) 2011-03-08
EP2301538B1 (en) 2015-05-20
US9273076B2 (en) 2016-03-01
EP1815206B1 (en) 2016-04-06
WO2006044505A2 (en) 2006-04-27
KR20070067165A (ko) 2007-06-27
US8710031B2 (en) 2014-04-29
WO2006044682A1 (en) 2006-04-27
BRPI0516110A (pt) 2008-08-26
WO2006044503A3 (en) 2006-07-06
CA2583159A1 (en) 2006-04-27
EP1815206A1 (en) 2007-08-08
US20170204073A1 (en) 2017-07-20
US9315467B2 (en) 2016-04-19
EP2301536A1 (en) 2011-03-30
EP1812071A2 (en) 2007-08-01
US20090203752A1 (en) 2009-08-13
EP2363129A1 (en) 2011-09-07
US20110160164A1 (en) 2011-06-30
EP3067053A1 (en) 2016-09-14
EP2402323A2 (en) 2012-01-04
KR20070067201A (ko) 2007-06-27
US20080269191A1 (en) 2008-10-30
CA2582885A1 (en) 2006-04-27
KR20070065429A (ko) 2007-06-22
AU2005295727A1 (en) 2006-04-27
IL182461A0 (en) 2007-10-31
IL182464A0 (en) 2008-04-13
MX2007004484A (es) 2007-06-25
WO2006044502A3 (en) 2006-08-03
EP1799212A2 (en) 2007-06-27
JP2008515990A (ja) 2008-05-15
EP2311455A1 (en) 2011-04-20
WO2006044456A1 (en) 2006-04-27
AU2005295730A1 (en) 2006-04-27
EP2316452A1 (en) 2011-05-04
US20140235586A1 (en) 2014-08-21
EP1799659A1 (en) 2007-06-27
WO2006044502A2 (en) 2006-04-27
EP2939674A1 (en) 2015-11-04
CA2583177A1 (en) 2006-04-27
SG156640A1 (en) 2009-11-26
SG156641A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
SG156641A1 (en) Compounds for nonsense suppression, and methods for their use
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
PL1742644T3 (pl) Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MXPA05013016A (es) Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
WO2007130501A3 (en) Combination therapy for treatment of cancer
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2006096759A3 (en) Methods and compositions for treating cancer
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
MX2010003615A (es) Tratamiento de desordenes neurologicos.
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors